Table 1 Occurrence of contrast features from the model for malignancy prediction
Contrast features (Method) | Â | Xenograft types Occurrence (frequency %) | ||
|---|---|---|---|---|
| Â | Â | Malignant | Benign | |
| Â | Â | MDA-MB 231 | MCF-7 | Â |
Molecular targeting contrast | CD31 (IHC) | 5/5 (100Â %) | 6/6 (100Â %) | 0/11 (0Â %) |
| Â | VEGF (IHC) | 5/5 (100Â %) | 6/6 (100Â %) | 0/11 (0Â %) |
Non-targeting contrast | Rim enhancement (DCE-MDCT) | 11/11 (100Â %) | 11/12 (100Â %) | 2/23 (8.7Â %) |
| Â | Time-density curve | Â | Â | Â |
Washout T1/2 < 100 min (DCE-MDCT) | 10/11 (90.9 %) | 10/12 (83.3 %) | 0/23 (0 %) | |
Endogenous contrast | Angular/ill-defined margin (grey scale US) | 9/10 (90Â %) | 14/17 (82.4Â %) | 0/27 (0Â %) |
| Â | Angular/ill-defined margin (DCE-MDCT) | 10/11 (90.9Â %) | 9/12 (75Â %) | 1/23 (4.3Â %) |
| Â | Orientation | Â | Â | Â |
width/height > 2.2 (grey scale US) | 10/10 (100 %) | 17/17 (100 %) | 0/27 (0 %) | |
| Â | Neovascular flow (color Doppler US) | 1/10 (10Â %) | 3/17 (17.6Â %) | 0/27 (0Â %) |